{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:53:58Z","timestamp":1782226438050,"version":"3.54.5"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction<\/jats:bold><jats:bold>:<\/jats:bold> Targeted medication, including mostly biologics and small-molecule chemical drugs, is an important therapy for ankylosing spondylitis (AS). There are still limited data on the preference of different targeted drugs in Chinese AS patients.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold><jats:bold>:<\/jats:bold> A questionnaire-based cross-sectional study was performed on AS patients from six hospitals in three provinces in South China. Anti-rheumatic diseases\u2019 medication history includes the recent and previous usage of biologics or Janus kinase inhibitors (JAKi) in the last complete course of treatment, disease severity, and reasons for targeted-treatment change or preference.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold><jats:bold>:<\/jats:bold> 354 of 366 participants responded to the online survey. The participants\u2019 median age was 32\u00a0years, with a median of 7.3\u00a0years of disease duration; 79.7% were male. 63.6% of them were in the course of biologics or JAKi. Generic ETN is the most widely used and willing-to-use biologic though the proportion of its usage shrunk in the present compared with the past. The choice of original-branded ADA demonstrated an increase in usage. The preference of secukinumab and tofacitinib depicted a quick ascending trend.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold><jats:bold>:<\/jats:bold> TNF-\u03b1 inhibitors (TNFi) are still the most popular targeted medication for AS in China. Their price influences patients\u2019 preferences mostly. The doctor\u2019s recommendation is also part of the equation. Rheumatologists should pay more attention to patients\u2019 education to formulate targeted therapeutic plans.<\/jats:p>","DOI":"10.3389\/fphar.2021.763707","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:32:10Z","timestamp":1635406330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey"],"prefix":"10.3389","volume":"12","author":[{"given":"Yiquan","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengquan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the Double-Blind, Randomised, Phase 3 MAXIMISE Trial","volume":"80","author":"Baraliakos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: A Review in Ankylosing Spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 Update of the ASAS\/EULAR Recommendations for the Management of Ankylosing Spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: Long-Term Safety in 23 458 Patients from Global Clinical Trials in Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis and Crohn's Disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-Term Safety of Secukinumab in Patients with Moderate-To-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B6","first-page":"2286","article-title":"A New Approach to Defining Disease Status in Ankylosing Spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/03009742.2018.1444199","article-title":"Biological Treatment in Ankylosing Spondylitis in the Nordic Countries during 2010-2016: A Collaboration between Five Biological Registries","volume":"47","author":"Glintborg","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study","volume":"163","author":"Haroon","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e00318","DOI":"10.1002\/prp2.318","article-title":"Make up a Missed Lesson-New Policy to Ensure the Interchangeability of Generic Drugs in China","volume":"5","author":"Huang","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease (*)","volume":"27","author":"Masters","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/ph13100324","article-title":"Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany","volume":"13","author":"Moorkens","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1759720X18793317","article-title":"The Role of Golimumab in Inflammatory Arthritis. A Review of the Evidence","volume":"10","author":"Tahir","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor Necrosis Factor Antagonist Mechanisms of Action: a Comprehensive Review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in Patients with Ankylosing Spondylitis: A Phase II, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.763707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:32:12Z","timestamp":1635406332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.763707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":15,"alternative-id":["10.3389\/fphar.2021.763707"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.763707","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"763707"}}